Archives of Virology

, Volume 102, Issue 3–4, pp 187–196

The gerbil, Meriones unguiculatus, a model for Rift Valley fever viral encephalitis

  • G. W. AndersonJr.
  • T. W. SloneJr.
  • C. J. Peters
Original Papers


The gerbil,Meriones unguiculatus, was investigated as a model for the encephalitic form of Rift Valley fever. Resistance to necrotizing encephalitis was age-dependent with 100% mortality at 3 weeks, decreasing to approximately 20% by 10 weeks of age in outbred gerbils inoculated subcutaneously. Fatal encephalitis in the 10-week-old adults was dose-independent [1.0–7.0 log10 plaque forming units (PFU), subcutaneously]. Viral replication and histological lesions were followed serially throughout the course of the infection in young (4 week) and adult (10 week) gerbils. Viral replication was evident in the brain tissue of young gerbils from day 4 (3.0 log10 PFU/g) through day 7 (6.0 log10 PFU/g), the last day the young gerbils survived. Virus was only detected in the brain tissue of a single adult gerbil (day 7, 4.0 log10 PFU/g) of 26 studied in the sequential survey. In contrast, two moribund adult gerbils had approximately 7.0 log10 PFU/g of virus in the brain tissue on days 8 and 11. When young and adult gerbils were inoculated with a low dose (50 PFU) of virus intracranially, there were no detectable differences in the course of infection with all animals succumbing to fatal necrotizing encephalitis aproximately 7 days postinoculation. The young gerbil becomes the first animal model in which uniformly fatal RVFV-induced encephalitis is produced without significant extraneural lesions.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anderson GW Jr, Smith JF (1987) Immunoelectron microscopy of Rift Valley fever viral morphogenesis in primary rat hepatocytes. Virology 161: 91–100Google Scholar
  2. 2.
    Anderson GW Jr, Slone TW Jr, Peters CJ (1987) Pathogenesis of Rift Valley fever virus in inbred rats. Microbial Pathogen 2: 283–293Google Scholar
  3. 3.
    Balducci M, Fausto AM, Verani P, Caciolli S, Renzi A, Paci P, Amaducci L, Leoncini F, Volpi G (1985) Phlebotomus-transmitted viruses in Europe. Comparative studies on their biology, ecology, epidemiology, and pathogenicity. In: Pozzi L (eds) Proc Int Cong Infect Dis, Cairo, Edizioni Luigi Pozzi, Rome, pp 101–104Google Scholar
  4. 4.
    Centers for Disease Control and National Institutes of Heath (1984) Biosafety in microbiological and biomedical laboratories, 1st edn. U.S. Department of Health and Human Services, Public Health Services, Washington, D.C., pp 74–89Google Scholar
  5. 5.
    Earley E, Peralta PH, Johnson KM (1967) A plaque neutralization method for arboviruses. Proc Soc Exp Biol Med 125: 741–747Google Scholar
  6. 6.
    Ehrnst A, Peters CJ, Niklasson B, Svedmyr A, Holmgren B (1985) Neurovirulent Toscana virus (a sandfly fever virus) in Swedish man after visit to Portugal. Lancet 1: 1212–1213Google Scholar
  7. 7.
    Johnson RT (1982) Viral infections of the nervous system. Raven Press, New York, pp 37–56Google Scholar
  8. 8.
    Kitchen SF (1950) The development of neurotropisms in Rift Valley fever virus. Ann Trop Med Parasitol 44: 132–145Google Scholar
  9. 9.
    Laughlin LW, Girgis NI, Meegan JM, Strausbaugh LJ, Jassin MW, Watten RH (1978) Clinical studies on Rift Valley fever: 2. Ophtalmologic and central nervous system complications. Egypt Public Health Assoc 53: 183–184Google Scholar
  10. 10.
    Maar SA, Swanepoel R, Gelfand M (1979) Rift Valley fever encephalitis. A description of a case. Cent Afr J Med 25: 8–11Google Scholar
  11. 11.
    Peters CJ, LeDuc JW (1984) Bunyaviruses, Phleboviruses and related viruses. In: Belshe RB (ed) Textbook of human virology. PSG Publishing Company, Inc., Littleton, pp 547–598Google Scholar
  12. 12.
    Peters CJ, Meegan JM (1981) Rift Valley fever. In: Beran GW, Steele JH (eds) CRC handbook series in zoonoses, vol 1. CRC Press, Boca Raton, pp 403–423Google Scholar
  13. 13.
    Peters CJ, Reynolds JA, Slone TW, Jones DE, Stephen EL (1986) Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antivir Res 6: 285–297Google Scholar
  14. 14.
    Peters CJ, Anderson GW Jr (1981) Pathogenesis of Rift Valley fever. In: Swartz TA, Klingberg MA, Goldblum N (eds) Contributions to epidemiology and biostatistics, S Karger, New York, pp 21–41Google Scholar
  15. 15.
    Peters CJ, Slone Jr TW (1982) Inbred rat strains mimic the disparate human response to Rift Valley fever virus infection. J Med Virol 10: 45–54Google Scholar
  16. 16.
    Smith JF, Pifat D (1982) Morphogenesis of Sandfly fever viruses (Bunyaviridae family). Virology 121: 61–81Google Scholar
  17. 17.
    Smithburn KC (1949) Rift Valley fever virus: the neurotropic adaptation of virus and experimental use of this modified virus as a vaccine. Br J Exp Pathol 30: 1–16Google Scholar
  18. 18.
    Subcommittee on Arbovirus Laboratory Safety of the American Committee on Arthropod-borne Viruses (1980) Laboratory safety for Arboviruses and certain other viruses of vertebrates. Am J Trop Med Hyg 29: 1359–1381Google Scholar
  19. 19.
    Velden DJJ, Meyer JD, Oliver J, Gear JHS, McIntosh B (1977) Rift Valley fever affecting humans in South Africa: a clinicopathological study. S Afr Med J 52: 417–418Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • G. W. AndersonJr.
    • 1
  • T. W. SloneJr.
    • 2
  • C. J. Peters
    • 1
  1. 1.Disease AssessmentUnited States Army Medical Research Institute of Infectious Diseases, Fort DetrickFrederickU.S.A.
  2. 2.Pathology DivisionsUnited States Army Medical Research Institute of Infectious Diseases, Fort DetrickFrederickU.S.A.
  3. 3.Hascall LaboratoriesNewarkU.S.A.

Personalised recommendations